Page last updated: 2024-10-25

cilostazol and Hemorrhage

cilostazol has been researched along with Hemorrhage in 43 studies

Hemorrhage: Bleeding or escape of blood from a vessel.

Research Excerpts

ExcerptRelevanceReference
"DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS."9.69Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023)
"In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding."9.69Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023)
"Cilostazol is feasible in acute ischemic stroke, and comparable to aspirin in its efficacy and safety."9.15Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011)
" We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation."9.15Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011)
"Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients."7.96Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020)
"The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats."7.80Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014)
"It seems that these results showed the safety and efficacy of the enteric-coated aspirin in acute stroke care in Japanese patients."7.80Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
"In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase."7.78Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012)
"These platelets enhance thrombus formation at the sites of endothelial disruption."6.43Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005)
"DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS."5.69Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023)
"In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding."5.69Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023)
" The addition of cilostazol to clopidogrel may provide a more rapid decrease in PRU to therapeutic levels without increasing the risk of hemorrhage."5.30DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. ( Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS, 2019)
"Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications."5.22Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022)
" Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0."5.22Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022)
"Cilostazol is feasible in acute ischemic stroke, and comparable to aspirin in its efficacy and safety."5.15Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011)
" We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation."5.15Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011)
"Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD)."5.13Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). ( Brass, EP; Hiatt, WR; Money, SR, 2008)
"Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack."4.93Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016)
"Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients."3.96Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020)
"Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding."3.88Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. ( Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC, 2018)
"Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0."3.84Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009)
"Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period."3.83Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016)
"We used data from the FRENA Registry to compare the clinical outcome in stable outpatients with intermittent claudication, according to the use of cilostazol."3.80Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014)
"It seems that these results showed the safety and efficacy of the enteric-coated aspirin in acute stroke care in Japanese patients."3.80Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
"The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats."3.80Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014)
"In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase."3.78Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012)
"Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades."2.52Clinical efficacy and safety of cilostazol: a critical review of the literature. ( Finks, SW; Oliphant, CS; Rogers, KC, 2015)
"Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis."2.52Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."2.50Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
"These platelets enhance thrombus formation at the sites of endothelial disruption."2.43Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005)
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."1.51The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)
"Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China."1.42Cilostazol research in Asia: can it be applied to European and American patients? ( Kim, JS; Kwon, SU; Uchiyama, S, 2015)
"6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17."1.39Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013)
"Mice subjected to 6-h middle cerebral artery occlusion were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h."1.36Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. ( Chen, H; Fujiwara, Y; Hara, H; Ishiguro, M; Iwama, T; Izuta, H; Mishiro, K; Satoh, M; Shimazawa, M; Tsuruma, K; Yoshimura, S, 2010)
" At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly."1.34Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (16.28)29.6817
2010's28 (65.12)24.3611
2020's8 (18.60)2.80

Authors

AuthorsStudies
Manolis, AA1
Manolis, TA1
Melita, H1
Mikhailidis, DP1
Manolis, AS1
Uchiyama, S4
Toyoda, K2
Okamura, S1
Omae, K1
Hoshino, H2
Kimura, K2
Kitagawa, K1
Minematsu, K2
Yamaguchi, T2
Tornyos, D1
Komócsi, A1
Bálint, A1
Kupó, P1
El Abdallaoui, OEA1
Szapáry, L1
Szapáry, LB1
Liu, H1
Shao, T1
Yang, T1
Li, D1
Wang, H1
Cheng, Y1
Zhang, T1
Zhang, J1
Nishiyama, Y1
Otsuka, T1
Sakai, N1
Okada, Y1
Origasa, H1
Naritomi, H1
Houkin, K1
Yamaguchi, K1
Matsumoto, M1
Tominaga, T1
Tomimoto, H1
Terayama, Y1
Yasuda, S1
Neishi, M1
Hamano, H1
Niimura, T1
Denda, M1
Yagi, K1
Miyata, K1
Lin, TJ1
Higashionna, T1
Goda, M1
Zamami, Y1
Ishizawa, K1
Nawa, H1
Kim, W1
Kim, JS4
Rha, SW2
Choi, BG1
Jang, WY1
Kang, DO1
Park, Y2
Choi, JY1
Roh, SY1
Na, JO1
Choi, CU1
Kim, EJ1
Park, CG1
Seo, HS1
Choi, SY1
Byun, JK1
Cha, J1
Oh, DJ1
Jeong, MH2
Dai, C1
Chen, Z1
Fu, J1
Qian, J1
Ge, J1
Jang, HJ1
Park, SD1
Park, HW1
Suh, J1
Oh, PC1
Moon, J1
Lee, K1
Kang, WC1
Kwon, SW1
Kim, TH1
Real, J1
Serna, MC1
Giner-Soriano, M1
Forés, R1
Pera, G1
Ribes, E1
Alzamora, M1
Marsal, JR1
Heras, A1
Morros, R1
Daimon, S1
Wu, Z1
Liu, AF1
Zhou, J1
Zhang, Y2
Wang, K1
Li, C1
Qiu, H1
Jiang, WJ1
Zhao, S1
Zhong, Z1
Qi, G1
Shi, L1
Tian, W1
Chen, YC1
Lin, FY1
Lin, YW1
Cheng, SM1
Lin, RH1
Chuang, CL1
Sheu, JS1
Chen, SM1
Chang, CC1
Tsai, CS1
Lee, HJ1
Yu, CW1
Hwang, HK1
Choi, RK1
Park, JS1
Li, H1
Ro, YM1
Park, KW1
Kang, SH1
Park, JJ1
Yang, HM1
Kang, HJ1
Koo, BK1
Park, BE1
Cha, KS1
Rhew, JY1
Jeon, HK1
Shin, ES1
Oh, JH1
Kim, S1
Hwang, KK1
Yoon, JH1
Lee, SY1
Park, TH1
Moon, KW1
Kwon, HM1
Chae, IH1
Kim, HS1
Chen, Y1
Tang, Y1
Huang, X1
Xie, Y1
Nakagawa, I2
Wada, T2
Park, HS2
Nishimura, F1
Yamada, S2
Nakagawa, H1
Kichikawa, K2
Nakase, H2
Takahashi, S1
Mizuno, O1
Sakaguchi, T1
Yamada, T1
Inuyama, L1
Perez, P1
Esteban, C1
Sauquillo, JC1
Yeste, M1
Manzano, L1
Mujal, A1
Jiménez Caballero, PE1
Aguilar, E1
Sánchez Muñoz-Torrero, JF1
Monreal, M1
Takeuchi, K1
Takayama, S1
Izuhara, C1
Kwon, SU2
Rogers, KC1
Oliphant, CS1
Finks, SW1
Bundhun, PK1
Qin, T1
Chen, MH1
Noh, Y1
Lee, J1
Shin, S1
Lim, HS1
Bae, SK1
Oh, E1
Kim, GJ1
Kim, JH1
Lee, S1
Niu, PP1
Guo, ZN1
Jin, H1
Xing, YQ1
Yang, Y1
Otoshi, T1
Kataoka, Y1
Nakagawa, A1
Otsuka, K1
Tomii, K1
Zuliani Mauro, MF1
Mangione, JA1
Costa, JR1
Costa, R1
Piva E Mattos, LA1
Staico, R1
Feres, F1
Siqueira, D1
Sousa, A1
Abizaid, A1
Yokoyama, S1
Motoyama, Y1
Tamhane, U1
Meier, P1
Chetcuti, S1
Chen, KY1
Grossman, MP1
Gurm, H1
Jeong, YH1
Kim, IS1
Yun, SE1
Kang, MK1
Hwang, SJ1
Kwak, CH1
Hwang, JY1
Ishiguro, M1
Mishiro, K1
Fujiwara, Y1
Chen, H1
Izuta, H1
Tsuruma, K1
Shimazawa, M1
Yoshimura, S1
Satoh, M1
Iwama, T1
Hara, H1
Ahn, CM1
Hong, SJ1
Park, JH1
Lim, DS1
Lee, YS1
Bae, HJ1
Kang, DW1
Lee, SH1
Yu, K1
Park, JM1
Cho, YJ1
Hong, KS1
Kim, DE1
Lee, KB1
Rha, JH1
Koo, J1
Han, MG1
Lee, SJ1
Lee, JH1
Jung, SW1
Lee, BC1
Pant, S1
Neupane, P1
Ramesh, KC1
Barakoti, M1
Hase, Y1
Okamoto, Y1
Fujita, Y1
Kitamura, A1
Nakabayashi, H1
Ito, H1
Maki, T1
Washida, K1
Takahashi, R1
Ihara, M1
Geng, DF1
Liu, M1
Jin, DM1
Wu, W1
Deng, J1
Wang, JF1
Goto, S2
Nakamura, T1
Yamazaki, M1
Kimura, Y1
Iwata, M1
Liao, JK1
Hong, EH1
Kim, MY1
Park, JE1
Lee, MH1
Oh, JM1
Shin, WG1
Hiatt, WR1
Money, SR1
Brass, EP1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02101411]334 participants (Actual)Observational2015-01-01Completed
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]Phase 43,750 participants (Anticipated)Interventional2010-06-30Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke[NCT00272454]Phase 4468 participants (Anticipated)Interventional2006-01-31Completed
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]Phase 4164 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects

MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization. (NCT02101411)
Timeframe: 24 months

Interventionnumbers of participants with MACE (Number)
Aspirin+Clopidogrel1
Aspirin+Ticagrelor1
Aspirin+Clopidogrel+Cilostazol2

Change From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.065
Cilostazol + Placebo0.896

Change From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.001
Cilostazol + Placebo0.815

Change From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.241
Cilostazol + Placebo0.134

Change From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.267
Cilostazol + Placebo0.145

Change From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.166
Cilostazol + Placebo0.139

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine13.20
Cilostazol + Placebo6.57

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine12.98
Cilostazol + Placebo10.01

Reviews

12 reviews available for cilostazol and Hemorrhage

ArticleYear
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:3

    Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination;

2022
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
    PloS one, 2022, Volume: 17, Issue:8

    Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S

2022
Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials.
    Clinical drug investigation, 2019, Volume: 39, Issue:1

    Topics: Cilostazol; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarctio

2019
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Current medical research and opinion, 2014, Volume: 30, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans

2014
Clinical efficacy and safety of cilostazol: a critical review of the literature.
    Drugs, 2015, Volume: 75, Issue:4

    Topics: Animals; Cilostazol; Hemorrhage; Humans; Intermittent Claudication; Peripheral Arterial Disease; Pla

2015
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
    BMC cardiovascular disorders, 2015, Oct-09, Volume: 15

    Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu

2015
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    BMJ open, 2016, Mar-17, Volume: 6, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische

2016
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis

2009
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil

2012
Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
    Atherosclerosis. Supplements, 2005, Dec-15, Volume: 6, Issue:4

    Topics: Bleeding Time; Cilostazol; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregatio

2005
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Circulation, 2007, Mar-27, Volume: 115, Issue:12

    Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr

2007
[Basic principal of the dual antithrombotic therapy achieved by cilostazol].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Oct-28, Volume: 64 Suppl 7

    Topics: Cilostazol; Hemorrhage; Humans; Phosphodiesterase Inhibitors; Tetrazoles; Thrombosis; Vasodilator Ag

2006

Trials

11 trials available for cilostazol and Hemorrhage

ArticleYear
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
    International journal of stroke : official journal of the International Stroke Society, 2023, Volume: 18, Issue:4

    Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi

2023
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
    Stroke, 2023, Volume: 54, Issue:3

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male;

2023
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male;

2019
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:9

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy,

2013
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona

2017
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
    Neurological research, 2017, Volume: 39, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati

2017
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis

2009
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F

2010
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
    Heart and vessels, 2011, Volume: 26, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona

2011
Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 32, Issue:1

    Topics: Aged; Aspirin; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage

2011
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Journal of vascular surgery, 2008, Volume: 47, Issue:2

    Topics: Aged; Cardiovascular Diseases; Cilostazol; Double-Blind Method; Female; Hemorrhage; Humans; Intermit

2008

Other Studies

21 other studies available for cilostazol and Hemorrhage

ArticleYear
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
    Journal of atherosclerosis and thrombosis, 2023, Aug-01, Volume: 30, Issue:8

    Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic

2023
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
    Toxicology and applied pharmacology, 2023, 09-15, Volume: 475

    Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related S

2023
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Heart and vessels, 2020, Volume: 35, Issue:9

    Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy

2020
Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:5

    Topics: Aspirin; China; Cilostazol; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy

2020
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
    Drugs & aging, 2017, Volume: 34, Issue:6

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male;

2017
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
    BMC cardiovascular disorders, 2018, 05-08, Volume: 18, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol;

2018
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2019, Volume: 23, Issue:1

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolyti

2019
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag

2019
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Coronary artery disease, 2013, Volume: 24, Issue:7

    Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb

2013
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Journal of vascular surgery, 2014, Volume: 59, Issue:3

    Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag

2014
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
    Advances in therapy, 2014, Volume: 31, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole

2014
Cilostazol and outcome in outpatients with peripheral artery disease.
    Thrombosis research, 2014, Volume: 134, Issue:2

    Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male;

2014
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
    Life sciences, 2014, Aug-21, Volume: 110, Issue:2

    Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggre

2014
Cilostazol research in Asia: can it be applied to European and American patients?
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10 Suppl 1

    Topics: Asia; Cilostazol; Europe; Hemorrhage; Humans; Intracranial Arteriosclerosis; Phosphoric Diester Hydr

2015
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human

2016
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
    Lung, 2016, Volume: 194, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female

2016
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
    PloS one, 2010, Dec-06, Volume: 5, Issue:12

    Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Cyclic Nucleotide Phosphodiest

2010
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Cardiology journal, 2011, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan

2011
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
    Experimental neurology, 2012, Volume: 233, Issue:1

    Topics: Administration, Oral; Animals; Antigens, CD; Brain; Brain Edema; Brain Ischemia; Calcium-Binding Pro

2012
New modalities and aspects of antiplatelet therapy for stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 21 Suppl 1

    Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi

2006
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:6

    Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar

2007